Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
88 studies found for:    myeloma AND (women OR woman OR female)
Show Display Options
Rank Status Study
1 Not yet recruiting Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
Conditions: Venous Thromboembolism;   Multiple Myeloma
Interventions: Drug: Apixaban;   Drug: Placebo Oral Tablet
2 Terminated A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: 5.0g SRT501;   Drug: Bortezomib
3 Active, not recruiting Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
Condition: Newly Diagnosed Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Lenalidomide;   Drug: Dexamethasone
4 Not yet recruiting Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Dexamethasone
5 Withdrawn A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Sotatercept;   Drug: Placebo
6 Recruiting Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
Condition: MULTIPLE MYELOMA (MM)
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Lenalidomide;   Drug: Dexamethasone
7 Active, not recruiting Agriculture Health Study
Conditions: Prostate Cancer;   Pesticide Exposure;   Lymphoma;   Multiple Myeloma
Intervention:
8 Not yet recruiting Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Thalidomide;   Drug: Dexamethasone
9 Active, not recruiting Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: Dendritic Cell Tumor Fusion
10 Recruiting Study of MLN9708 Plus Oral Dexamethasone or Plus Oral Cyclophosphamide and Dexamethasone or Plus Bendamustine and Dexamethasone or Plus Oral Thalidomide and Dexamethasone Followed by Maintenance With MLN9708 in Newly Diagnosed Elderly Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Bendamustine;   Drug: Thalidomide
11 Completed A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Conditions: Lymphoma, Mantle-cell;   Leukemia, Lymphocytic, Chronic, B-Cell;   Leukemia, Hairy Cell;   Waldenstrom Macroglobulinemia;   Multiple Myeloma
Intervention: Drug: ON01910 Na
12 Terminated Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.
Conditions: Vertebral Fracture;   Multiple Myeloma;   Osteolytic Metastases
Intervention: Device: balloon kyphoplasty
13 Completed Protein Tyrosine Kinases (PTK) in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: PTK787/ZK222584
14 Completed The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: Dendritic Cell Tumor Fusion Vaccine
15 Recruiting Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: ACE-011;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Pomalidomide
16 Completed Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
Condition: Cancer
Interventions: Dietary Supplement: Vitamin D;   Dietary Supplement: Calcium
17 Completed Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
18 Active, not recruiting Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Plerixafor (AMD3100);   Drug: bortezomib
19 Completed Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
Condition: Multiple Myeloma
Intervention: Drug: Zoledronic acid
20 Recruiting A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Bortezomib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.